Could a breast cancer drug help fight liposarcoma?
NCT ID NCT02846987
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called abemaciclib in 33 people with dedifferentiated liposarcoma, a rare soft tissue cancer that has spread or cannot be removed by surgery. The drug aims to slow tumor growth or shrink it by at least a quarter. Abemaciclib is not yet approved for this cancer, but has shown promise in other cancers like breast and lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abemaciclib (a targeted cancer drug)
What this could lead to
If it works, this could offer a new treatment option for people with dedifferentiated liposarcoma that has spread or come back.
What could go wrong
This is an early Phase 2 trial with only 33 people. Abemaciclib has not been tested in liposarcoma before, so it may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States